Coeptis Therapeutics Hldgs Inc (COEP) Stock Price, Quote & News

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology

Sector: Healthcare

Phone: 724 934 6467

Website: coeptistx.com

Address:

105 Bradford Road, Suite 420, Wexford, United States

Fluteman_Greg Apr. 25 at 1:00 PM

$COEP Checked my Schwab account, COEP has been changed to ZSQR. Anyone know how the spinoff works? How do COEP shareholders monetize that? Can't find anything that explains how that vehicle works.

0 · Reply

daviddoe123 Apr. 25 at 8:57 AM

$COEP anyone have a feeling that @The1Albatross ditchsd this play

1 · Reply

Herrm Apr. 25 at 7:07 AM

$COEP

0 · Reply

kobramaximus Apr. 25 at 1:38 AM

$COEP To everyone who held the line for the last 12 months.. we made it. Biotech spin-off secured. Nasdaq Global Market upgrade secured. Monday starts a new chapter. Cheers to the real OGs who knew what we had. See you on the other side. Special thanks to @The1Albatross who never steered us wrong CHEEEE-HUUU aloha to da gains my braddah!!! 🤙🏾🏄🏾‍♂️🌊

1 · Reply

WonkyGorilla Apr. 25 at 12:58 AM

$COEP ITS HALTED ON RH.. BOOM BOOM SAUCE TIME MONDAY!! ☝🏻

1 · Reply

Jjsgoofy Apr. 25 at 12:35 AM

$COEP

0 · Reply

Herrm Apr. 24 at 9:48 PM

$COEP

0 · Reply

Fezza123 Apr. 24 at 9:42 PM

$COEP Monday

0 · Reply

RoyalImperial Apr. 24 at 9:25 PM

MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $POET $COEP $RENX $GLND ...11

0 · Reply

daviddoe123 Apr. 24 at 9:22 PM

$COEP only 15% rip

1 · Reply

Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market

Apr 7, 2026, 12:05 PM EDT - 17 days ago

Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application

Feb 5, 2026, 4:00 PM EST - 2 months ago

Coeptis Receives Shareholder Approval Towards Z Squared Merger

Jan 6, 2026, 8:19 AM EST - 3 months ago

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

Sep 23, 2025, 8:00 AM EDT - 7 months ago

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Jul 22, 2025, 8:36 AM EDT - 9 months ago

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Jun 26, 2025, 8:34 AM EDT - 10 months ago

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

May 28, 2025, 8:28 AM EDT - 11 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Apr 25, 2025, 8:33 AM EDT - 1 year ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 17, 2025, 8:38 AM EDT - 1 year ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Mar 11, 2025, 8:34 AM EDT - 1 year ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 7, 2025, 8:37 AM EST - 1 year ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 1 year ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

Feb 20, 2025, 9:00 AM EST - 1 year ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 7:27 AM EST - 1 year ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 13, 2025, 8:39 AM EST - 1 year ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 6, 2025, 8:08 AM EST - 1 year ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Jan 30, 2025, 8:27 AM EST - 1 year ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 23, 2025, 8:09 AM EST - 1 year ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Jan 22, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jan 7, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Dec 27, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Announces Reverse Stock Split

Dec 26, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 3, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Nov 7, 2024, 8:07 AM EST - 1 year ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Oct 24, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 15, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Sep 19, 2024, 7:07 AM EDT - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 5, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Jun 20, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

May 30, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

May 8, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

May 2, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Apr 2, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Feb 26, 2024, 9:00 AM EST - 2 years ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 7, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Jan 4, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Dec 4, 2023, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Oct 24, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Oct 9, 2023, 9:15 AM EDT - 2 years ago

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

$Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection$

Sep 14, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Sep 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Aug 30, 2023, 1:00 PM EDT - 2 years ago

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Aug 17, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Fluteman_Greg Apr. 25 at 1:00 PM

$COEP Checked my Schwab account, COEP has been changed to ZSQR. Anyone know how the spinoff works? How do COEP shareholders monetize that? Can't find anything that explains how that vehicle works.

0 · Reply

daviddoe123 Apr. 25 at 8:57 AM

$COEP anyone have a feeling that @The1Albatross ditchsd this play

1 · Reply

Herrm Apr. 25 at 7:07 AM

$COEP

0 · Reply

kobramaximus Apr. 25 at 1:38 AM

1 · Reply

WonkyGorilla Apr. 25 at 12:58 AM

$COEP ITS HALTED ON RH.. BOOM BOOM SAUCE TIME MONDAY!! ☝🏻

1 · Reply

Jjsgoofy Apr. 25 at 12:35 AM

$COEP

0 · Reply

Herrm Apr. 24 at 9:48 PM

$COEP

0 · Reply

Fezza123 Apr. 24 at 9:42 PM

$COEP Monday

0 · Reply

RoyalImperial Apr. 24 at 9:25 PM

0 · Reply

daviddoe123 Apr. 24 at 9:22 PM

$COEP only 15% rip

1 · Reply

TwongStocks Apr. 24 at 9:01 PM

$COEP Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market https://www.prnewswire.com/news-releases/z-squared-announces-completion-of-business-combination-with-coeptis-therapeutics-and-listing-on-the-nasdaq-global-market-302753341.html

0 · Reply

DesseinH Apr. 24 at 7:27 PM

$COEP We about to get paid! Remember, that dividend alone is worth 12$!!! My cash drop go cha ching!

0 · Reply

daviddoe123 Apr. 24 at 7:17 PM

$COEP looking like a sell the news lmao

0 · Reply

daviddoe123 Apr. 24 at 6:42 PM

$COEP buy the news or sell the news?

1 · Reply

TwongStocks Apr. 24 at 6:30 PM

$COEP Equity Corporate Actions Alert #2026 - 277 Information Regarding the Business Combination of Coeptis Therapeutics Holdings Inc. (COEP) & Z Squared Inc. https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-277 The business combination of Coeptis Therapeutics Holdings Inc. (COEP) & Z Squared Inc. is expected to close today, Friday, April 24, 2026. Following the completion of the business combination, the company's Common stock (COEP) will undergo a name, symbol, and CUSIP number change and the company's Warrants (COEPW) will be suspended from trading. These actions will become effective on Monday, April 27, 2026. The combined company will list on the Nasdaq Global Market. Subject to closing. New Name: Z Squared Inc. New Symbol: $ZSQR

2 · Reply

Mich2029 Apr. 24 at 6:22 PM

$COEP Monday? Just noticed this on Schwab

1 · Reply

PS600REVX Apr. 24 at 6:13 PM

$COEP ruh roh

1 · Reply

Sookie1962 Apr. 24 at 4:32 PM

$COEP i see some are buying Warrants for this stock iam just curious why how warrants per share are dose anyone know this information and are willing to share??

0 · Reply

terrystocker Apr. 24 at 3:34 PM

@The1Albatross when do you expect $COEP ticker to change?

1 · Reply

The1Albatross Apr. 23 at 11:32 PM

$COEP Hate to flood but y’all know how I stay with the play and deeply appreciate the folks that follow and stand up. Making money with fellow minded bulls is the bonus and reason I share all conviction plays. Cheers to us amigos

6 · Reply

AllAmerican82ndAirborne Apr. 23 at 10:36 PM

$COEP $NEOV If any of you ever feel like you want to harm yourselves, just take one look at my account and you will feel better 😂🫩 and no, I still have not learned to take profits 🤝

3 · Reply

ReversedRunners Apr. 23 at 7:45 PM

$COEP $CADL $BETR $CJET ^*^

0 · Reply

Market Cap	100.88M
Revenue (ttm)	1.36M
Net Income (ttm)	-11.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-876.47%
Debt to Equity Ratio	0.01

Volume	111,100
Avg Vol	49,682
Day's Range	N/A - N/A
Shares Out	6.22M
Stochastic %K	84%
Beta	-0.44
Analysts	Strong Buy
Price Target	$3.00